Algert Global LLC purchased a new position in Exactech, Inc. (NASDAQ:EXAC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,776 shares of the medical equipment provider’s stock, valued at approximately $1,454,000.

Other institutional investors have also recently bought and sold shares of the company. Kirr Marbach & Co. LLC IN increased its position in Exactech by 1.2% in the first quarter. Kirr Marbach & Co. LLC IN now owns 10,760 shares of the medical equipment provider’s stock worth $271,000 after buying an additional 125 shares during the last quarter. American International Group Inc. increased its position in Exactech by 7.1% in the first quarter. American International Group Inc. now owns 6,423 shares of the medical equipment provider’s stock worth $162,000 after buying an additional 424 shares during the last quarter. ClariVest Asset Management LLC increased its position in Exactech by 5.4% in the first quarter. ClariVest Asset Management LLC now owns 10,908 shares of the medical equipment provider’s stock worth $275,000 after buying an additional 554 shares during the last quarter. Bessemer Group Inc. increased its position in Exactech by 5.4% in the second quarter. Bessemer Group Inc. now owns 19,400 shares of the medical equipment provider’s stock worth $578,000 after buying an additional 1,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Exactech by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 36,617 shares of the medical equipment provider’s stock worth $923,000 after buying an additional 2,612 shares during the last quarter. 64.68% of the stock is currently owned by institutional investors and hedge funds.

Shares of Exactech, Inc. (NASDAQ:EXAC) opened at 28.45 on Wednesday. Exactech, Inc. has a 52 week low of $22.20 and a 52 week high of $31.90. The stock has a market capitalization of $407.43 million, a PE ratio of 547.12 and a beta of 1.02. The company’s 50 day moving average price is $29.94 and its 200-day moving average price is $27.91.

Exactech (NASDAQ:EXAC) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $67.75 million. Exactech had a return on equity of 7.45% and a net margin of 0.30%. Exactech’s quarterly revenue was up 1.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.31 EPS. Equities research analysts predict that Exactech, Inc. will post $1.29 EPS for the current year.

WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/09/algert-global-llc-purchases-new-stake-in-exactech-inc-exac.html.

A number of equities analysts have recently issued reports on the company. Gabelli reissued a “buy” rating on shares of Exactech in a research report on Monday, July 31st. TheStreet raised Exactech from a “c+” rating to a “b” rating in a research report on Tuesday, April 25th. Zacks Investment Research raised Exactech from a “sell” rating to a “hold” rating in a research report on Tuesday, April 25th. Finally, BidaskClub cut Exactech from a “hold” rating to a “sell” rating in a research note on Monday, July 31st.

In other Exactech news, Director William B. Locander sold 988 shares of the stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $30.34, for a total transaction of $29,975.92. Following the sale, the director now owns 8,555 shares in the company, valued at approximately $259,558.70. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Joel C. Phillips sold 7,610 shares of the stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $30.71, for a total value of $233,703.10. Following the sale, the chief financial officer now owns 99,907 shares in the company, valued at approximately $3,068,143.97. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,345 shares of company stock worth $284,894. 28.30% of the stock is owned by insiders.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Want to see what other hedge funds are holding EXAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exactech, Inc. (NASDAQ:EXAC).

Institutional Ownership by Quarter for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.